Literature DB >> 11693848

In vitro monodisperse aerosol deposition in a mouth and throat with six different inhalation devices.

W H DeHaan1, W H Finlay.   

Abstract

Experiments were performed to determine the effect of different pharmaceutical aerosol inhalation devices on the deposition of monodisperse aerosols in an idealized mouth and throat geometry. The devices included two dry powder inhalers (Diskus and Turbuhaler), two nebulizers (Pari LC STAR and Hudson T-Updraft), and a metered dose inhaler with attached holding chamber (Aerochamber), in addition to a straight tube (1.7 cm inner diameter). Aerosol particles (DL-alpha tocopheryl acetate) of diameters of 2.5, 5, and 7 microm generated by a vibrating orifice generator were inhaled at steady air flow rates of Q = 5-90 L/min through the devices and into the mouth-throat. Deposition in the mouth-throat and after-filter were determined by ultraviolet (UV) spectrophotometric assay. The amount of deposition in the mouth and throat region was found to depend on the type of device that the aerosol entered through. Deposition in the extrathoracic region with the two types of jet nebulizers did not differ significantly (p > 0.1) from that of a straight tube or each other over their entire tested range of 590 > or = pd2Q > or = 11,375, where p is particle density (in g/cm3), d is particle diameter (in microm), and Q is flow rate (in cm3/s). The metered dose inhaler with attached holding chamber was found to differ from the straight tube only at two intermediate values of pd2Q = 5,145 and 16,033. The deposition occurring for the dry powder inhalers was found to be significantly greater than for the straight tube for all values of pd2Q > or = 10,954 for the Diskus and pd2Q > or = 9,435 for the Turbuhaler. Deposition with the dry powder inhalers was found to be up to 14 times greater than that with the straight tube. Thus, the inhaler geometry that the aerosol passes through prior to entering the mouth and throat region can greatly affect the deposition in the mouth-throat.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11693848     DOI: 10.1089/089426801316970321

Source DB:  PubMed          Journal:  J Aerosol Med        ISSN: 0894-2684


  13 in total

1.  Suitability of the upper airway models obtained from MRI studies in simulating drug lung deposition from inhalers.

Authors:  T Ehtezazi; K W Southern; D Allanson; I Jenkinson; C O'Callaghan
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

2.  Comparison of deposition in the USP and physical mouth-throat models with solid and liquid particles.

Authors:  Yue Zhou; Jaijie Sun; Yung-Sung Cheng
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2011-07-06       Impact factor: 2.849

Review 3.  In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory Approaches.

Authors:  Ben Forbes; Per Bäckman; David Christopher; Myrna Dolovich; Bing V Li; Beth Morgan
Journal:  AAPS J       Date:  2015-05-05       Impact factor: 4.009

Review 4.  Mechanisms of pharmaceutical aerosol deposition in the respiratory tract.

Authors:  Yung Sung Cheng
Journal:  AAPS PharmSciTech       Date:  2014-02-22       Impact factor: 3.246

Review 5.  In silico models of aerosol delivery to the respiratory tract - development and applications.

Authors:  P Worth Longest; Landon T Holbrook
Journal:  Adv Drug Deliv Rev       Date:  2011-05-27       Impact factor: 15.470

6.  Near Elimination of In Vitro Predicted Extrathoracic Aerosol Deposition in Children Using a Spray-Dried Antibiotic Formulation and Pediatric Air-Jet DPI.

Authors:  Dale Farkas; Morgan L Thomas; Amr Hassan; Serena Bonasera; Michael Hindle; Worth Longest
Journal:  Pharm Res       Date:  2022-06-27       Impact factor: 4.200

7.  In Vitro and In Silico Investigations on Drug Delivery in the Mouth-Throat Models with Handihaler®.

Authors:  Fen Huang; Xudong Zhou; Wen Dai; Jiaqi Yu; Zongyan Zhou; Zhenbo Tong; Aibing Yu
Journal:  Pharm Res       Date:  2022-09-07       Impact factor: 4.580

8.  Development of characteristic upper tracheobronchial airway models for testing pharmaceutical aerosol delivery.

Authors:  Ross L Walenga; Geng Tian; P Worth Longest
Journal:  J Biomech Eng       Date:  2013-09       Impact factor: 2.097

9.  High-Efficiency Dry Powder Aerosol Delivery to Children: Review and Application of New Technologies.

Authors:  Karl Bass; Dale Farkas; Amr Hassan; Serena Bonasera; Michael Hindle; P Worth Longest
Journal:  J Aerosol Sci       Date:  2020-10-14       Impact factor: 3.433

10.  In vitro performance testing of the novel Medspray wet aerosol inhaler based on the principle of Rayleigh break-up.

Authors:  Anne H de Boer; Jeroen Wissink; Paul Hagedoorn; Iwan Heskamp; Wilbur de Kruijf; Ralf Bünder; Pieter Zanen; Paul Munnik; Cees van Rijn; Henderik W Frijlink
Journal:  Pharm Res       Date:  2007-12-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.